World News

The approval grants the pharmaceutical giant the right to market Enflonsia across all 27 member states of the European Union, as well as Iceland, Liechtenstein, and Norway.

The summit convenes senior executives from healthcare, biotechnology, artificial intelligence, academia, and investment firms under the theme “Healthtech Frontiers: Building the Health Ecosystem of Tomorrow.”

Less than 10% of participants in the Nuvaxovid group experienced severe side effects that interfered with daily activities compared with 20% in the mNexspike group.

By integrating Aicuris into its global development and commercialization infrastructure, Asahi Kasei accelerates its expansion in the specialty pharmaceutical sector.

The updated platform now connects customers with companies such as Twin Health, Curai Health, Wheel, Berry Street, and Aaptiv.

MyGenius PRO adds to Bruker’s molecular diagnostics portfolio, which includes InGenius, BeGenius, and LiquidArray assays.

The agreement also includes potential clinical, regulatory, and commercial milestone payments that could raise the total value to USD7 billion,

Biogen now holds worldwide rights to the investigational therapy, felzartamab, which is currently undergoing Phase 3 clinical trials for several immune-mediated diseases.

The therapy, known as NRTX-1001, uses pluripotent stem cells engineered to regulate brain activity and repair damaged neural networks.

The Phase Ib/II trial will assess safety, tolerability, and early signs of clinical activity. Researchers will combine Boehringer Ingelheim’s investigational T-cell engager, obrixtamig, with Zai Lab’s antibody-drug conjugate (ADC), zocilurtatug pelitecan (zoci).